Harnessing new targets and mechanisms mediating AD pathogenesis

利用介导 AD 发病机制的新靶点和机制

基本信息

  • 批准号:
    10590789
  • 负责人:
  • 金额:
    $ 36.84万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2022
  • 资助国家:
    美国
  • 起止时间:
    2022-12-01 至 2027-11-30
  • 项目状态:
    未结题

项目摘要

Alzheimer’s disease (AD) is an incurable neurodegenerative brain disorder that causes progressive memory loss and cognitive decline, and is the No.1 cause of dementia. It is characterized by the coexistence of extracellular amyloid plaques, mainly formed by the amyloid beta-42 (Abeta) peptide, and intracellular neurofibrillary tangles containing aggregates of abnormal tau. Abeta and tau were considered as disconnected culprits for many years, but in view of recent studies, it is clear that they are intimately related and possess synergistic activities. Sadly, very little is known about how Abeta and tau interactions trigger AD pathogenesis, which significantly hinders the development of effective treatments. To address this, we generated a new fly model of AD that genetically produces both human Abeta and tau resulting in synergistic pathology. These flies display extracellular deposits of thioflavin-S-positive Abeta, intracellular aggregation and phosphorylation of wild-type tau, and progressive loss of neuronal cells. The robust and consistent pathology of these flies provides a unique opportunity for gene discovery efforts and thus we performed a massive loss-of-function RNAi screen in the fly eye, which provides a useful and easy-to-score phenotype. Out of 6,600 RNAi stocks tested, we identified 31 suppressors and 119 enhancers, including multiple genes not previously known to be associated with AD. Most suppressors are linked to protein modification or cleavage, ribosomal function, cell metabolism, transcription, chromatin modulation, and transport to name a few. Here, we will employ a strategically designed pipeline that integrates genetics with high-throughput behavioral platforms and target prioritization to identify robust late-stage modifiers of the disease (Aim 1). On the other hand, we will fast-track a mechanistic and therapeutic analysis of one of the strongest suppressors along with its human homologue (Aim 2). This suppressor encodes a highly disordered protein of uncharacterized function and was also found in two other genetic screens performed by us. Thus, we have labelled it as a high-priority target. We strongly believe that manipulation of the 150 modifiers of Abeta+tau toxicity presented here will provide the foundation for new types of targets or therapeutics. Therefore, this work may contribute significantly to the goals of the National Plan to Address Alzheimer’s Disease.
阿尔茨海默病(AD)是一种无法治愈的神经退行性脑部疾病,会导致进行性记忆丧失和认知能力下降,是痴呆症的第一大病因。其特征是细胞外淀粉样斑块(主要由淀粉样蛋白β -42 (Abeta)肽形成)和细胞内含有异常tau聚集物的神经原纤维缠结共存。多年来,Abeta和tau被认为是互不关联的罪魁祸首,但鉴于最近的研究,它们显然是密切相关的,并具有协同作用。遗憾的是,我们对Abeta和tau相互作用如何引发AD发病机制知之甚少,这极大地阻碍了有效治疗方法的发展。为了解决这个问题,我们建立了一种新的AD苍蝇模型,该模型在遗传上产生人类β和tau蛋白,从而导致协同病理。这些果蝇表现出硫黄素- s阳性β的细胞外沉积,细胞内聚集和野生型tau的磷酸化,以及神经元细胞的进行性损失。这些果蝇的强大和一致的病理为基因发现工作提供了一个独特的机会,因此我们在果蝇眼睛中进行了大量的功能缺失RNAi筛选,这提供了一个有用且易于评分的表型。在测试的6600个RNAi库存中,我们确定了31个抑制子和119个增强子,包括多个以前不知道与AD相关的基因。大多数抑制因子与蛋白质修饰或切割、核糖体功能、细胞代谢、转录、染色质调节和运输等有关。在这里,我们将采用一种战略性设计的管道,将遗传学与高通量行为平台和目标优先级结合起来,以确定疾病的强大晚期修饰因子(目的1)。另一方面,我们将快速追踪其中一种最强的抑制因子及其人类同源物的机制和治疗分析(目标2)。该抑制因子编码一种功能不明确的高度紊乱蛋白,在我们进行的另外两个遗传筛选中也发现了该抑制因子。因此,我们把它列为高度优先的目标。我们坚信,本文提出的150种Abeta+tau毒性修饰剂的操作将为新型靶点或治疗方法提供基础。因此,这项工作可能对解决阿尔茨海默病国家计划的目标作出重大贡献。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Diego E Rincon-Limas其他文献

Diego E Rincon-Limas的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Diego E Rincon-Limas', 18)}}的其他基金

Functional assessment of 1,500 human genes against coexistent Abeta and tau pathology in vivo
针对体内共存的 Abeta 和 tau 病理学对 1,500 个人类基因进行功能评估
  • 批准号:
    10224098
  • 财政年份:
    2020
  • 资助金额:
    $ 36.84万
  • 项目类别:
Functional assessment of 1,500 human genes against coexistent Abeta and tau pathology in vivo
针对体内共存的 Abeta 和 tau 病理学对 1,500 个人类基因进行功能评估
  • 批准号:
    10053894
  • 财政年份:
    2020
  • 资助金额:
    $ 36.84万
  • 项目类别:
Deconstructing and challenging TDP-43 proteinopathies: from FTLD/ALS to Alzheimer's disease
解构和挑战 TDP-43 蛋白病:从 FTLD/ALS 到阿尔茨海默病
  • 批准号:
    10408106
  • 财政年份:
    2018
  • 资助金额:
    $ 36.84万
  • 项目类别:
Deconstructing and challenging TDP-43 proteinopathies: from FTLD/ALS to Alzheimer's disease
解构和挑战 TDP-43 蛋白病:从 FTLD/ALS 到阿尔茨海默病
  • 批准号:
    9918238
  • 财政年份:
    2018
  • 资助金额:
    $ 36.84万
  • 项目类别:
Deconstructing and challenging TDP-43 proteinopathies: from FTLD/ALS to Alzheimer's disease
解构和挑战 TDP-43 蛋白病:从 FTLD/ALS 到阿尔茨海默病
  • 批准号:
    9759749
  • 财政年份:
    2018
  • 资助金额:
    $ 36.84万
  • 项目类别:
Deconstructing and challenging TDP-43 proteinopathies: from FTLD/ALS to Alzheimer's disease
解构和挑战 TDP-43 蛋白病:从 FTLD/ALS 到阿尔茨海默病
  • 批准号:
    10180834
  • 财政年份:
    2018
  • 资助金额:
    $ 36.84万
  • 项目类别:
Uncovering targets that block pathological interactions between Abeta and tau
发现阻断 Abeta 和 tau 之间病理性相互作用的靶点
  • 批准号:
    9373909
  • 财政年份:
    2017
  • 资助金额:
    $ 36.84万
  • 项目类别:
Targeting nuclear transport dysfunction in TDP-43 proteinopathies
靶向 TDP-43 蛋白病中的核转运功能障碍
  • 批准号:
    9246585
  • 财政年份:
    2016
  • 资助金额:
    $ 36.84万
  • 项目类别:
Targeting nuclear transport dysfunction in TDP-43 proteinopathies
靶向 TDP-43 蛋白病中的核转运功能障碍
  • 批准号:
    9092579
  • 财政年份:
    2016
  • 资助金额:
    $ 36.84万
  • 项目类别:
Optogenetic modeling of primary and secondary CNS proteinopathies in Drosophila
果蝇原发性和继发性中枢神经系统蛋白病的光遗传学模型
  • 批准号:
    8771014
  • 财政年份:
    2014
  • 资助金额:
    $ 36.84万
  • 项目类别:

相似海外基金

Interplay between Aging and Tubulin Posttranslational Modifications
衰老与微管蛋白翻译后修饰之间的相互作用
  • 批准号:
    24K18114
  • 财政年份:
    2024
  • 资助金额:
    $ 36.84万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
The Canadian Brain Health and Cognitive Impairment in Aging Knowledge Mobilization Hub: Sharing Stories of Research
加拿大大脑健康和老龄化认知障碍知识动员中心:分享研究故事
  • 批准号:
    498288
  • 财政年份:
    2024
  • 资助金额:
    $ 36.84万
  • 项目类别:
    Operating Grants
EMNANDI: Advanced Characterisation and Aging of Compostable Bioplastics for Automotive Applications
EMNANDI:汽车应用可堆肥生物塑料的高级表征和老化
  • 批准号:
    10089306
  • 财政年份:
    2024
  • 资助金额:
    $ 36.84万
  • 项目类别:
    Collaborative R&D
関節リウマチ患者のSuccessful Agingに向けたフレイル予防対策の構築
类风湿性关节炎患者成功老龄化的衰弱预防措施的建立
  • 批准号:
    23K20339
  • 财政年份:
    2024
  • 资助金额:
    $ 36.84万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Baycrest Academy for Research and Education Summer Program in Aging (SPA): Strengthening research competencies, cultivating empathy, building interprofessional networks and skills, and fostering innovation among the next generation of healthcare workers t
Baycrest Academy for Research and Education Summer Program in Aging (SPA):加强研究能力,培养同理心,建立跨专业网络和技能,并促进下一代医疗保健工作者的创新
  • 批准号:
    498310
  • 财政年份:
    2024
  • 资助金额:
    $ 36.84万
  • 项目类别:
    Operating Grants
Life course pathways in healthy aging and wellbeing
健康老龄化和福祉的生命历程路径
  • 批准号:
    2740736
  • 财政年份:
    2024
  • 资助金额:
    $ 36.84万
  • 项目类别:
    Studentship
I-Corps: Aging in Place with Artificial Intelligence-Powered Augmented Reality
I-Corps:利用人工智能驱动的增强现实实现原地老龄化
  • 批准号:
    2406592
  • 财政年份:
    2024
  • 资助金额:
    $ 36.84万
  • 项目类别:
    Standard Grant
NSF PRFB FY 2023: Connecting physiological and cellular aging to individual quality in a long-lived free-living mammal.
NSF PRFB 2023 财年:将生理和细胞衰老与长寿自由生活哺乳动物的个体质量联系起来。
  • 批准号:
    2305890
  • 财政年份:
    2024
  • 资助金额:
    $ 36.84万
  • 项目类别:
    Fellowship Award
虚弱高齢者のSuccessful Agingを支える地域課題分析指標と手法の確立
建立区域问题分析指标和方法,支持体弱老年人成功老龄化
  • 批准号:
    23K20355
  • 财政年份:
    2024
  • 资助金额:
    $ 36.84万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
「ケア期間」に着目したbiological aging指標の開発
开发聚焦“护理期”的生物衰老指数
  • 批准号:
    23K24782
  • 财政年份:
    2024
  • 资助金额:
    $ 36.84万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了